CVP |
6 cycles |
16 |
Partial response |
Rituximab (start 8/9/2001) |
8 cycles |
31 |
Complete
response |
Rituximab (start 4/2004) |
5 cycles |
15 |
Partial
response |
Radiation Therapy |
2000 cGy in 10 fractions |
1 |
Stable
disease |
Everolimus trial (start 1/2007) |
12 months |
12 |
Stable
disease |
Lenalidomide start 9/27/2010) |
5 months |
5 |
Partial
response |
Rituximab (start 2/2011) |
8 cycles |
11 |
Stable
disease |
Lenalidomide (start 1/2012) |
28 months |
28 |
Complete
response |
PI3K delta Inhibitor trial (6/2014) |
6 months |
6 |
Partial
response |
Gemcitabine and Oxaliplatin (start 12/30/2014) |
7 cycles |
19 |
Partial response |
Axicabtagene ciloleucel (9/2018) |
N/A |
20 |
Complete
response |
Axicabtagene ciloleucel (6/2020) |
N/A |
2 |
Partial
response |
BCL-2 inhibitor trial |
2 weeks |
0 |
No
response |
Obinutuzumab and Lenalidomide |
5 cycles |
Ongoing
(>6) |
Complete response |
Lenalidomide maintenance |
Ongoing |
Ongoing (>6) |
Complete response |